FibroBiologics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
FibroBiologics, Inc. (FBLG) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $707.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-31
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $707.00K, a 3.02% decline year-over-year.
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $694.00K, a 25.95% increase year-over-year.
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $704.00K, a 23.08% increase year-over-year.
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $729.00K, a 26.12% increase year-over-year.
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.69M, a 23.55% increase from fiscal 2024.
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.17M, a 23.17% increase from fiscal 2023.
- FibroBiologics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.76M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $707.00K 10-Q · filed 2026-07-31 | $1.40M derived: sum of 2 quarters · filed 2026-07-31 | ||
| 2026-03-31 | $694.00K 10-Q · filed 2026-07-31 | |||
| 2025-12-31 | $2.69M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $704.00K 10-Q · filed 2025-10-31 | $1.43M derived: sum of 2 quarters · filed 2026-07-31 | $1.98M derived: sum of 3 quarters · filed 2026-07-31 | |
| 2025-06-30 | $729.00K 10-Q · filed 2026-07-31 | $1.28M derived: sum of 2 quarters · filed 2026-07-31 | ||
| 2025-03-31 | $551.00K 10-Q · filed 2026-07-31 | |||
| 2024-12-31 | $2.17M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $572.00K 10-Q · filed 2025-10-31 | $1.15M derived: sum of 2 quarters · filed 2025-10-31 | $1.63M derived: sum of 3 quarters · filed 2025-10-31 | |
| 2024-06-30 | $578.00K 10-Q · filed 2025-10-31 | $1.06M derived: sum of 2 quarters · filed 2025-10-31 | ||
| 2024-03-31 | $480.00K 10-Q · filed 2025-10-31 | |||
| 2023-12-31 | $1.76M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $437.00K 10-Q · filed 2024-11-12 | $885.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.33M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $448.00K 10-Q · filed 2024-11-12 | $896.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $448.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |